Current Headlines

  1. Sun Pharma Licenses Merck’s Psoriasis Drug For $80M
    9/18/2014

    Merck announced that it has entered into a licensing agreement with Indian generics company Sun Pharmaceuticals for Merck’s therapeutic antibody candidate tildrakizumab as treatment for chronic plaque psoriasis.

  2. Mylan, Gilead Partner To Bring Cheaper Hepatitis C Treatment To Developing Countries
    9/18/2014

    In a new collaboration with Gilead Sciences, Mylan has won the nonexclusive rights to manufacture and distribute sofosbuvir and the investigational single tablet regimen of ledipasvir/sofosbuvir in 91 developing countries. Gilead currently markets Sovaldi, the brand-name version of sofosbuvir, indicated for those with hepatitis C.

  3. Biogen Idec Announces Strides In Clinical Studies For MS Treatments
    9/18/2014

    Biogen Idec announced clinical study results for three of its Multiple Sclerosis (MS) treatments at the sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis in Boston last week.

  4. EMD Serono, Sutro Biopharma Form ADC Partnership
    9/18/2014

    EMD Serono, a subsidiary of Merck, and Sutro Biopharma in San Francisco announced a new partnership to collaborate on the production of antibody drug conjugates (ADCs) for undisclosed cancerous targets.

  5. Avanir’s Drug Combination Reduces Agitation in Alzheimer’s Disease Patients
    9/18/2014

    Avanir Pharmaceuticals this week announced the positive results from its phase 2 clinical trial for its combination drug therapy AVP-923, which was successful in lowering agitation in patients with Alzheimer's disease.

  6. NIH Awards Grants In Cell Pathway Research For New Therapies
    9/17/2014

    The National Institutes of Health (NIH) announced that it has awarded more than $64 million in grants to six research institutions to advance understanding of cellular pathways and help in the development of new treatments.

  7. Akashi Acquires Global Rights To Tarantula Venom DMD Therapy
    9/17/2014

    Akashi announced that it had acquired global rights to GsMTx-4, an amino acid peptide toxin isolated from Grammostola rosea (Chilean rose) tarantula venom, in development with Tonus as a potential therapy for Duchenne Muscular Dystrophy (DMD).

  8. More Vaccines Needed For Tropical Diseases, Study Reveals
    9/17/2014

    There has been quite a clamor recently about the record-setting outbreak of the deadly Ebola virus in West Africa, which has killed over 2,200 people to date and spurred numerous strategies in an effort to control it, including a new vaccine and other experimental drugs.

  9. SELLAS Collaborates With MSK For New WT1 Cancer Vaccine
    9/17/2014

    Swiss-based biopharmaceutical company, SELLAS Life Sciences, announced that it has signed a global collaboration and license agreement with the Memorial Sloan Kettering Cancer Center (MSK) to develop, market, and commercialize MSK's new proprietary WT1 cancer vaccine.

  10. Researchers Discover Gene Targets In Emery-Dreifuss Muscular Dystrophy
    9/17/2014

    An international team of researchers has just discovered new genetic targets responsible for an incurable muscle-wasting disease, Emery-Dreifuss muscular dystrophy (EDMD).

Newsletter Signup
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.